```html

Zollinger–Ellison‑type Hyperacidity

Overview

Zollinger–Ellison‑type hyperacidity is a condition characterized by excessive production of stomach acid (gastric hydrochloric acid) due to a gastrin‑secreting tumor (gastrinoma) or, less commonly, extreme hyperstimulation of normal gastrin cells. The resulting acid load can overwhelm the protective mechanisms of the gastrointestinal (GI) tract, leading to severe peptic ulcers, diarrhea, and malabsorption.

Although the term “Zollinger–Ellison syndrome” (ZES) technically refers to the presence of gastrin‑producing neuroendocrine tumors, many clinicians use “Zollinger–Ellison‑type hyperacidity” to describe the clinical picture of high acid output regardless of tumor location. The condition is rare: the incidence of ZES is approximately 0.1–0.3 cases per 100,000 people per year, representing less than 1 % of all peptic‑ulcer disease cases [1] Mayo Clinic. Most patients are diagnosed between the ages of 30 and 60, with a slight male predominance.

Symptoms

Typical gastrointestinal complaints

• Recurrent or refractory peptic ulcers – ulcers that do not heal despite standard therapy.
• Epigastric (upper‑abdominal) pain – often described as burning, worsening 1–3 hours after meals.
• Heartburn/acid reflux – due to overwhelming acid spilling into the esophagus.
• Chronic diarrhea – acid inactivates pancreatic enzymes and damages intestinal mucosa, leading to steatorrhea.
• Nausea and vomiting – especially if ulcers ulcerate into the duodenum.

Systemic and less common manifestations

• Weight loss – from malabsorption and reduced appetite.
• Fatigue – secondary to anemia from chronic blood loss.
• Gastrointestinal bleeding – melena or hematemesis from ulcer erosion.
• Abdominal bloating and flatulence – due to maldigestion.
• Unexplained abdominal mass – a palpable tumor in the pancreas or duodenum (rare).

Causes and Risk Factors

The central driver of Zollinger–Ellison‑type hyperacidity is overproduction of gastrin, a hormone that stimulates parietal cells to secrete hydrochloric acid. The most common cause is a gastrinoma, a neuroendocrine tumor that arises in the pancreas, duodenum, or nearby lymph nodes. About 25 % of gastrinomas occur as part of the hereditary syndrome Multiple Endocrine Neoplasia type 1 (MEN‑1) [2] NIH.

Key risk factors include:

• Family history of MEN‑1 or other neuroendocrine tumors.
• Genetic mutations in the MEN1 gene.
• Previous history of chronic H. pylori infection or long‑term use of proton‑pump inhibitors (PPIs) – not causative, but may mask early symptoms and delay diagnosis.
• Age 30–60 (peak incidence), with a slight male predominance.

Diagnosis

Accurate diagnosis requires a combination of clinical suspicion, biochemical testing, and imaging.

1. Biochemical Confirmation

• Fasting serum gastrin level – Levels > 1,000 pg/mL (10 × the upper limit of normal) are highly suggestive, especially when the gastric pH is low (< 2). [3] Cleveland Clinic
• Secretin stimulation test – Intravenous secretin normally suppresses gastrin; in gastrinomas it paradoxically raises gastrin > 120 pg/mL. This test improves specificity when baseline gastrin is borderline.
• Gastric pH measurement – A pH < 2 confirms acid hypersecretion.

2. Imaging for Tumor Localization

• Multiphasic contrast‑enhanced CT scan – First‑line for detecting pancreatic or duodenal masses.
• Magnetic resonance imaging (MRI) with MRCP – Helpful for small lesions and liver metastases.
• Somatostatin receptor scintigraphy (OctreoScan) or ^68Ga‑DOTATATE PET/CT – High sensitivity for neuroendocrine tumors.
• Endoscopic ultrasound (EUS) – Allows fine‑needle aspiration for histology.

3. Endoscopic Assessment

Upper endoscopy (EGD) evaluates ulcer burden, obtains biopsies to rule out H. pylori or malignancy, and can provide direct visual evidence of multiple duodenal ulcers distal to the bulb – a classic ZES finding.

Treatment Options

Acid Suppression – The Cornerstone

Because the morbidity of ZES stems from acid injury, rapid and potent acid control is essential.

• Proton‑pump inhibitors (PPIs) – High‑dose omeprazole (40–80 mg daily) or equivalent (e.g., esomeprazole 40–80 mg). PPIs normalize gastric pH in > 90 % of patients [4] WHO.
• H2‑receptor antagonists – Often inadequate alone but may be used adjunctively.
• Potassium‑competitive acid blockers (e.g., vonoprazan) – Emerging data suggest rapid, sustained acid control, useful in refractory cases.

Surgical Management

When a tumor is localized and resectable, surgery offers the only potential cure.

• Enucleation or pancreaticoduodenectomy – Chosen based on tumor size, location, and involvement of surrounding structures.
• Debulking surgery – For metastatic disease; reduces gastrin production and improves symptom control.

In MEN‑1 patients, surgery is more controversial because of multifocal disease; many clinicians opt for medical control first and reserve surgery for symptomatic or rapidly growing tumors [5] NIH.

Systemic Therapies for Unresectable or Metastatic Disease

• Somatostatin analogues (octreotide, lanreotide) – Inhibit gastrin release and may shrink tumors.
• Targeted therapies (everolimus, sunitinib) – Approved for pancreatic neuroendocrine tumors; improve progression‑free survival.
• Peptide‑receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to receptor‑positive tumors.
• Chemotherapy – Reserved for high‑grade neuroendocrine carcinomas.

Lifestyle and Adjunctive Measures

• Avoid NSAIDs, aspirin, and other ulcerogenic drugs.
• Limit alcohol and caffeine, which can stimulate acid secretion.
• Eat small, frequent meals; avoid large fatty meals that delay gastric emptying.
• Stay hydrated – chronic diarrhea can lead to electrolyte loss.

Living with Zollinger–Ellison‑type Hyperacidity

Medication Adherence

Take PPIs exactly as prescribed—usually once or twice daily on an empty stomach. Do not discontinue abruptly; taper under physician guidance to avoid rebound hyperacidity.

Monitoring

• Follow‑up fasting gastrin levels every 6–12 months.
• Endoscopic surveillance every 1–2 years to check ulcer healing.
• Imaging (CT/MRI) annually if there is known disease or every 2 years if disease‑free.

Nutrition

• Consider a low‑fat, high‑protein diet to aid digestion.
• Supplement fat‑soluble vitamins (A, D, E, K) if malabsorption is present.
• Oral rehydration solutions for persistent diarrhea.

Psychosocial Support

Living with a rare chronic disease can be stressful. Join patient support groups (e.g., NET Cancer Support) and discuss anxiety or depression with your healthcare team.

Prevention

Because most cases arise from sporadic gastrinomas, primary prevention is limited. However, risk can be reduced through:

• Genetic counseling and early screening for individuals with a family history of MEN‑1.
• Eradicating Helicobacter pylori infection, which may lessen chronic gastrin stimulation.
• Avoiding long‑term use of ulcer‑causing medications unless medically indicated.

Complications

If uncontrolled, Zollinger–Ellison‑type hyperacidity can lead to serious health problems:

• Perforated duodenal ulcer – Acute abdomen requiring emergency surgery.
• Upper GI bleeding – Can cause anemia and hemodynamic instability.
• Severe chronic diarrhea – Leads to electrolyte disturbances (hypokalemia, metabolic alkalosis).
• Malabsorption and osteopenia – Acid inactivates pancreatic enzymes, decreasing nutrient absorption.
• Metastatic neuroendocrine tumor spread – Liver, lymph nodes, or bone metastases worsen prognosis.
• Refractory ulcer disease – May require lifelong high‑dose PPIs.

When to Seek Emergency Care

---

References: [1] Mayo Clinic. “Zollinger–Ellison syndrome.” Updated 2023. https://www.mayoclinic.org.
[2] National Institutes of Health (NIH). “Multiple Endocrine Neoplasia Type 1.” 2022. https://www.ncbi.nlm.nih.gov.
[3] Cleveland Clinic. “Gastrinoma (Zollinger–Ellison syndrome) Diagnosis.” 2024. https://my.clevelandclinic.org.
[4] World Health Organization (WHO). “Guidelines for the Management of Peptic Ulcer Disease.” 2023.
[5] NIH National Cancer Institute. “Neuroendocrine Tumors Treatment (PDQ®)–2024.” https://www.cancer.gov.

```